How to Get Testosterone Enanthate in Minnesota

Who Can Prescribe Testosterone Enanthate in Minnesota

Any Minnesota-licensed clinician with Schedule III prescriptive authority can write a testosterone enanthate prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). NPs in Minnesota gained full practice authority in 2015 under Minnesota Statute 148.235, meaning they can prescribe independently without a collaborative agreement.

For telehealth consultations, the prescribing clinician must hold an active Minnesota medical license or be registered under an applicable interstate compact. The Minnesota Board of Medical Practice requires that a legitimate provider-patient relationship be established before any controlled substance prescription is issued. A synchronous video visit satisfies this requirement. Audio-only visits may be accepted under certain payer policies, but video is the standard for initial TRT evaluations.

The Endocrine Society's 2018 clinical practice guideline recommends that testosterone therapy be prescribed by clinicians experienced in diagnosing and managing male hypogonadism. General practitioners can prescribe, though many patients prefer specialists in endocrinology or men's health for ongoing management.

Lab Requirements Before Starting Testosterone Enanthate

You will need at least two morning serum total testosterone measurements drawn before 10:00 a.m. Low testosterone is defined as a total testosterone level below 300 ng/dL on both draws, according to the American Urological Association. Single draws are insufficient because testosterone follows a circadian rhythm, peaking between 6:00 and 8:00 a.m. and dropping as much as 35% by afternoon.

Beyond testosterone levels, a prescribing clinician will typically order a complete baseline panel. This includes a complete blood count (CBC) with hematocrit, a comprehensive metabolic panel, a fasting lipid panel, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism. Men over 40 should have a prostate-specific antigen (PSA) test at baseline, as the Endocrine Society recommends PSA screening before initiating testosterone to establish a reference value.

Prolactin and estradiol levels may be drawn at the clinician's discretion. Elevated prolactin could suggest a pituitary adenoma requiring imaging, while baseline estradiol helps guide future monitoring for aromatization-related side effects. Free testosterone or sex hormone-binding globulin (SHBG) levels can also be ordered if total testosterone falls in the borderline range of 264 to 300 ng/dL, since high SHBG can mask a functional deficiency.

Quest Diagnostics and Labcorp both operate draw sites across Minnesota, including Minneapolis, St. Paul, Rochester, Duluth, and St. Cloud. Most telehealth TRT providers will send you a lab requisition that you can take to any network draw center. Results typically return within 48 to 72 hours.

The Telehealth Pathway for Testosterone Enanthate in Minnesota

Minnesota law permits telehealth prescribing of testosterone enanthate. The state adopted broad telehealth parity legislation in 2015 and expanded it during the COVID-19 public health emergency. Post-pandemic, telehealth prescribing of Schedule III substances remains legal provided the clinician establishes a provider-patient relationship through a real-time audio-visual encounter.

A typical telehealth TRT workflow in Minnesota follows this sequence. First, you complete an intake questionnaire covering symptoms (fatigue, low libido, depressed mood, reduced muscle mass), medical history, and current medications. Second, you receive a lab requisition and complete bloodwork at a local draw site. Third, you attend a video consultation where the clinician reviews your labs, symptoms, and clinical history. Fourth, if you meet diagnostic criteria, the clinician writes a prescription sent electronically to your chosen pharmacy.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine (N=790 men aged 65 and older), found that testosterone gel improved sexual function, physical activity, and mood over 12 months compared with placebo. While TTrials used transdermal testosterone, the findings established that confirmed hypogonadism warrants treatment. Testosterone enanthate delivers the same active hormone through a different route.

Several national telehealth platforms are licensed to prescribe in Minnesota. Turnaround from initial sign-up to first injection typically ranges from 7 to 14 days, depending on how quickly you complete labs and schedule the video consultation. Some platforms ship testosterone enanthate directly to your door via partnered 503A pharmacies, while others send the prescription to a local retail pharmacy.

Filling the Prescription: Retail and 503A Pharmacy Options

Once your clinician writes the prescription, you have two main pharmacy pathways in Minnesota. Retail chain pharmacies (CVS, Walgreens, Hy-Vee) stock commercially manufactured testosterone enanthate from generic manufacturers or the branded product Delatestryl. The typical cash price for a 5 mL vial of testosterone enanthate 200 mg/mL at a Minnesota retail pharmacy ranges from $40 to $90 without insurance, though prices fluctuate by location. GoodRx and similar discount cards can reduce out-of-pocket costs.

The second pathway involves 503A compounding pharmacies. Minnesota licenses 503A pharmacies under Minnesota Board of Pharmacy regulations. A 503A pharmacy compounds testosterone enanthate for an individual patient based on a valid prescription. Compounded testosterone enanthate may offer customized concentrations (for example, 250 mg/mL or 300 mg/mL) or different carrier oils (grapeseed oil vs. cottonseed oil) for patients with sensitivities. Several Minnesota-based 503A pharmacies ship statewide.

Because testosterone enanthate is a Schedule III controlled substance, electronic prescribing for controlled substances (EPCS) is required in Minnesota as of January 2021. Paper prescriptions are permitted only in specific exemption scenarios. Your clinician will transmit the prescription electronically to the pharmacy, which typically takes minutes. Refills are limited to five within six months under DEA regulations for Schedule III substances.

Minnesota Medicaid and Insurance Coverage

Minnesota Medicaid (Medical Assistance) covers testosterone enanthate for the diagnosis of male hypogonadism. Coverage requires prior authorization (PA). The PA process verifies that the patient has a confirmed diagnosis, documented low testosterone on at least two morning labs, and no absolute contraindications such as active prostate cancer, untreated polycythemia, or unstable heart failure.

The Endocrine Society's 2018 guideline explicitly recommends against prescribing testosterone to men who are planning fertility in the near term, as exogenous testosterone suppresses spermatogenesis. This contraindication is also evaluated during the PA review. For men seeking both TRT and fertility preservation, clinicians may prescribe alternatives like clomiphene citrate or human chorionic gonadotropin (hCG) off-label.

Commercial insurers in Minnesota, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and UCare, generally cover testosterone enanthate injections with PA. The documentation typically required for PA includes the two qualifying lab results, a clinical note documenting signs and symptoms of hypogonadism, and confirmation that the patient does not have a disqualifying condition. PA approvals are usually granted for 12 months, after which reauthorization requires updated labs.

The TRAVERSE trial, a cardiovascular safety study published in the New England Journal of Medicine (N=5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease), found that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo over a mean follow-up of 33 months. The hazard ratio for MACE was 0.96 (95% CI, 0.78 to 1.17). This data point has been used by clinicians and payers to support ongoing coverage of testosterone therapy in men with cardiovascular risk factors. Prior to TRAVERSE, some insurers had tightened PA criteria based on earlier FDA safety warnings.

Dosing, Administration, and What to Expect

The standard starting dose of testosterone enanthate for male hypogonadism is 100 to 200 mg administered by intramuscular injection once weekly or 200 to 400 mg every two weeks. The FDA-approved labeling specifies a dosing range of 50 to 400 mg every two to four weeks, though most current clinical protocols favor weekly injections to minimize peak-to-trough fluctuations in serum testosterone levels.

Weekly dosing produces more stable blood levels. A pharmacokinetic study showed that testosterone enanthate has a half-life of approximately 4.5 days when administered intramuscularly in an oil vehicle. Injecting every two weeks creates a pronounced peak within 24 to 48 hours followed by a gradual decline, which some patients experience as mood swings, energy crashes, or return of symptoms in the days before the next injection.

Injection sites typically include the vastus lateralis (outer thigh) or the ventrogluteal (upper outer buttock). Many patients self-inject at home after initial training by their clinician or a nurse. Needle gauges of 22 to 25 gauge with 1 to 1.5 inch length are standard for intramuscular injection. Subcutaneous injection of testosterone enanthate using a shorter needle (27 to 30 gauge, 0.5 inch) is an off-label but increasingly common practice supported by published data showing comparable serum levels.

Within four to six weeks, most men notice improvements in energy, mood, and libido. The Endocrine Society guideline notes that sexual function improvements may begin as early as three weeks, while body composition changes (increased lean mass, decreased fat mass) take three to six months to become measurable. Full effects on bone mineral density require 12 to 24 months of continuous therapy.

Ongoing Monitoring Requirements

After starting testosterone enanthate, Minnesota clinicians follow the Endocrine Society's monitoring protocol. A follow-up lab panel is drawn at 6 to 12 weeks after initiation, then every 6 to 12 months. The follow-up panel includes total testosterone (drawn midway between injections for biweekly dosing, or trough for weekly dosing), hematocrit, and PSA for men over 40.

Hematocrit is the most important safety lab. Testosterone stimulates erythropoiesis, and hematocrit levels above 54% increase the risk of thromboembolic events. The Endocrine Society recommends dose reduction or temporary cessation if hematocrit exceeds 54%, along with evaluation for sleep apnea, which independently raises hematocrit. In the TRAVERSE trial, polycythemia (hematocrit above 54%) occurred in 22.3% of men receiving testosterone compared with 2.0% in the placebo group over the study period.

PSA should be monitored annually. A PSA increase of more than 1.4 ng/mL within 12 months of starting testosterone, or an absolute PSA above 4.0 ng/mL, warrants urology referral. This threshold comes from the Endocrine Society guideline and is consistent with American Urological Association screening recommendations.

Estradiol monitoring is reasonable at the first follow-up visit, particularly in men with a BMI above 30, since adipose tissue contains aromatase enzyme that converts testosterone to estradiol. Symptoms of elevated estradiol include gynecomastia, water retention, and mood changes. Most clinicians target estradiol levels between 20 and 40 pg/mL during TRT.

Transferring a Prescription to Minnesota

If you already have an active testosterone enanthate prescription from another state, transferring it to a Minnesota pharmacy is possible but subject to specific rules. For Schedule III controlled substances, the receiving Minnesota pharmacy must verify the prescription with the originating pharmacy and ensure compliance with Minnesota Board of Pharmacy transfer regulations.

Because testosterone enanthate is a controlled substance, the transfer is limited to one transfer per prescription under federal DEA rules, unless the pharmacies share a real-time electronic database (as many chain pharmacies do). If you are moving to Minnesota permanently, the more reliable approach is to establish care with a Minnesota-licensed clinician who can write new prescriptions. Telehealth makes this straightforward; you can often complete a new patient evaluation within one to two weeks of arrival.

Minnesota participates in the Prescription Monitoring Program (PMP), and your clinician will check the Minnesota PMP database before prescribing. The PMP tracks all Schedule II through IV controlled substance dispensing in the state and shares data with neighboring states through PMP InterConnect.